Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

作者：Ludwig Heinz^*; Beksac Meral; Blade Joan; Cavenagh Jamie; Cavo Michele; Delforge Michel; Dimopoulos Meletios; Drach Johannes; Einsele Hermann; Facon Thierry; Goldschmidt Hartmut; Harousseau Jean Luc; Hess Urs; Kropff Martin; da Costa Fernando Leal; Louw Vernon; Magen Nativ Hila; Mendeleeva Larisa; Nahi Hareth; Plesner Torben; San Miguel Jesus; Sonneveld Pieter; Udvardy Miklos; Sondergeld Pia; Palumbo Antonio

来源：Oncologist, 2011, 16(4): 388-403.

DOI：10.1634/theoncologist.2010-0386

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403

• 出版日期2011
• 单位河北医科大学